Search
Deferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalDeferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesLomitapide
go.drugbank.com/drugs/DB08827Approved[A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity. … Unlike traditional statin therapy, which relies on the upregulation of LDL receptors to clear cholesterol, Lomitapide acts independently of the LDL receptor by preventing the assembly and secretion of
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 SubstratesTaurochenodeoxycholic acid
go.drugbank.com/drugs/DB08833ExperimentalTaurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile. As a medication, taurochenodeoxycholic acid reduces cholesterol fo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAgmatine
go.drugbank.com/drugs/DB08838ExperimentalAgmantine is a natural metabolite of the amino acid arginine. It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpiv...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTeriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalTeriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specific...
Synonyms: (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidideCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated b...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalEnzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic.
Categories: Androgen Receptor Antagonists, Androgen Receptor InhibitorsFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnFormestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersIndenolol
go.drugbank.com/drugs/DB08952ApprovedWithdrawnIndenolol is a drug of the beta-adrenergic blocker class.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates